MedTrace Logo

A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)

NCT00412958 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 125

Last updated 2014-12-17

Study results available
· View outcomes & findings →

Summary

A multicenter study to compare multiple doses of intravitreal microplasmin in patients undergoing surgical vitrectomy.

Conditions

  • Vitrectomy

Interventions

DRUG

Ocriplasmin 25µg

Intravitreal injection of 0.1 ml of ocriplasmin solution containing 25µg of ocriplasmin.

DRUG

Ocriplasmin 75µg

Intravitreal injection of 0.1 ml of ocriplasmin solution containing 75µg of ocriplasmin.

DRUG

Ocriplasmin 125µg

Intravitreal injection of 0.1 ml of ocriplasmin solution containing 125µg of ocriplasmin.

DRUG

Placebo

Intravitreal injection of placebo

Sponsors & Collaborators

  • ThromboGenics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00412958 on ClinicalTrials.gov